Nanomolar Potency Pyrimido-pyrrolo-quinoxalinedione CFTR Inhibitor Reduces Cyst Size in a Polycystic Kidney Disease Model
- 28 September 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (20), 6447-6455
- https://doi.org/10.1021/jm9009873
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Thiazolidinone CFTR inhibitors with improved water solubility identified by structure–activity analysisBioorganic & Medicinal Chemistry, 2008
- Nanomolar CFTR Inhibition by Pore-Occluding Divalent Polyethylene Glycol-Malonic Acid HydrazidesCell Chemical Biology, 2008
- Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2008
- Chloride channels as drug targetsNature Reviews Drug Discovery, 2008
- Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in choleraThe FASEB Journal, 2005
- Altered channel gating mechanism for CFTR inhibition by a high‐affinity thiazolidinone blockerFEBS Letters, 2004
- Antiparasitic activity of highly conjugated pyrimidine-2,4-dione derivativesIl Farmaco, 2003
- Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin–induced intestinal fluid secretionJCI Insight, 2002
- The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitroKidney International, 1996
- Reinvestigation of the synthesis of 3-dimethylallyl-4-hydroxy-2-quinolones. A novel route to tetracyclic heteroaromatic compoundsJournal of the Chemical Society, Perkin Transactions 1, 1977